Skip to main content
SpringerLink
Log in

Newer Calcium Channel Blockers

  • Chapter
  • First Online:
Hypertension and Cardiovascular Disease in Asia

Part of the book series: Updates in Hypertension and Cardiovascular Protection ((UHCP))

  • 967 Accesses

Abstract

Traditional calcium channel blockers (CCBs) such as diltiazem, verapamil and amlodipine have been in use for various indications for many years. Newer generations of CCBs, especially the dihydropyridines, were introduced in the 1990s, with special emphasis on their lipophilicity and dual blockade of calcium channels. There is plenty of clinical evidence supporting the advantages of newer L-/T- and L-/N-type CCBs over conventional L-type CCBs. However, this evidence may be biased in many ways due to the small sample size, short follow-up and open-label design of several studies. Due to the lack of large and long-term studies, data on cardiovascular outcomes and mortality is scarce for most of the newer agents. Conversely, amlodipine has been studied in several large, long-term trials, such as the antihypertensive lipid-lowering treatment to prevent heart attack trial that enrolled >33,000 patients and had a follow-up of about 5 years. In addition, the safety and efficacy of amlodipine for enhancing patient outcomes are firmly established. Despite the limitations of current clinical evidence, the novel CCBs herald a new era in antihypertensive therapy. More well-designed, large-scale and long-term clinical trials involving these agents are needed to aid clinicians in making a more informed decision about the most appropriate CCB for their patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Godfraind T. Discovery and development of calcium channel blockers. Front Pharmacol. 2017;8:286.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Fares H, DiNicolantonio JJ, O’Keefe JH, Lavie CJ. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart. 2016;3(2):e000473.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ozawa Y, Hayashi K, Kobori H. New generation calcium channel blockers in hypertensive treatment. Curr Hypertens Rev. 2006;2(2):103–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Wang AL, Iadecola C, Wang G. New generations of dihydropyridines for treatment of hypertension. J Geriatr Cardiol. 2017;14(1):67–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Tamargo J, Ruilope LM. Investigational calcium channel blockers for the treatment of hypertension. Expert Opin Investig Drugs. 2016;25(11):1295–309.

    Article  CAS  PubMed  Google Scholar 

  6. Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs. 2005;65(2):1–10.

    CAS  PubMed  Google Scholar 

  7. Fleckenstein A, Tritthart H, Flackenstein B, Herbst A, Grün G. A new group of competitive divalent Ca-antagonists (iproveratril, D 600, prenylamine) with potent inhibitory effects on electromechanical coupling in mammalian myocardium. Pflugers Arch. 1969;307(2):25.

    Google Scholar 

  8. Fleckenstein A, Tritthart H, Döring HJ, Byon KY. B [BAY a 1040--a highly potent Ca ++ -antagonistic inhibitor of electro-mechanical coupling processes in mammalian myocardium]. Arzneimittelforschung. 1972;22(1):22–33.

    CAS  PubMed  Google Scholar 

  9. Sueta D, Tabata N, Hokimoto S. Clinical roles of calcium channel blockers in ischemic heart diseases. Hypertens Res. 2017;40(5):423–8.

    Article  CAS  PubMed  Google Scholar 

  10. Wang J, McDonagh DL, Meng L. Calcium channel blockers in acute care: the links and missing links between hemodynamic effects and outcome evidence. Am J Cardiovasc Drugs. 2021;21(1):35–49.

    Article  PubMed  Google Scholar 

  11. Aouam K, Berdeaux A. Dihydropyridines from the first to the fourth generation: better effects and safety. Therapie. 2003;58(4):333–9.

    Article  PubMed  Google Scholar 

  12. Chandra KS, Ramesh G. The fourth-generation calcium channel blocker: cilnidipine. Indian Heart J. 2013;65(6):691–5.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Katz AM. Pharmacology and mechanisms of action of calcium-channel blockers. J Clin Hypertens. 1986;2(3):28–37.

    Google Scholar 

  14. Godfraind T. Calcium channel blockers in cardiovascular pharmacotherapy. J Cardiovasc Pharmacol Ther. 2014;19(6):501–15.

    Article  CAS  PubMed  Google Scholar 

  15. Singh BN, Hecht HS, Nademanee K, Chew CY. Electrophysiologic and hemodynamic effects of slow-channel blocking drugs. Prog Cardiovasc Dis. 1982;25(2):103–32.

    Article  CAS  PubMed  Google Scholar 

  16. Singh BN, Nademanee K, Baky SH. Calcium antagonists. Clinical use in the treatment of arrhythmias. Drugs. 1983;25(2):125–53.

    Article  CAS  PubMed  Google Scholar 

  17. Aftab K, Arain AA, Memon AAR, Memon AR, Phull QZ, Ansari MA. Evaluation of the anti platelet aggregation effects of diltiazem. J Pharmacol Clin Res. 2016;1(5):555–71.

    Article  Google Scholar 

  18. Xie W, Zheng F, Evangelou E, Liu O, Yang Z, Chan Q, et al. Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis. J Hypertens. 2018;36(6):1256–65.

    Article  CAS  PubMed  Google Scholar 

  19. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA. 1983;250(18):2500–2.

    Article  CAS  PubMed  Google Scholar 

  20. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341(19):1447–57.

    Article  CAS  PubMed  Google Scholar 

  21. Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens. 2011;29(7):1270–80.

    Article  CAS  PubMed  Google Scholar 

  22. Pedrinelli R, Dell’Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J Hum Hypertens. 2001;15(7):455–61.

    Article  CAS  PubMed  Google Scholar 

  23. Keating GM. Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings. Drugs. 2014;74(16):1947–60.

    Article  CAS  PubMed  Google Scholar 

  24. Tanaka H, Shigenobu K. Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels. Cardiovasc Drug Rev. 2002;20(1):81–92.

    Article  CAS  PubMed  Google Scholar 

  25. Kario K, Sato Y, Shirayama M, Takahashi M, Shiosakai K, Hiramatsu K, Komiya M, Shimada K. Inhibitory effects of azelnidipine tablets on morning hypertension. Drugs. 2013;13(1):63–73.

    CAS  Google Scholar 

  26. Yao K, Nagashima K, Miki H. Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker. J Pharmacol Sci. 2006;100(4):243–61.

    Article  CAS  PubMed  Google Scholar 

  27. Management of Hypertension. Indian guidelines on hypertension-IV. J Assoc Phys. 2019;67(Suppl):22–9.

    Google Scholar 

  28. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens. 2003;5(1):58–63.

    Article  CAS  Google Scholar 

  29. Tiwaskar M, Langote A, Kashyap R, Toppo A. Amlodipine in the era of new generation calcium channel blockers. J Assoc Phys. 2018;66(3):64–9.

    Google Scholar 

  30. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.

    Article  PubMed  CAS  Google Scholar 

  31. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, et al. The valsartan antihypertensive long-term use evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006;48(3):385–91.

    Article  CAS  PubMed  Google Scholar 

  32. Lacourcière Y, Poirier L, Lefebvre J, Archambault F, Cléroux J, Boileau G. Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension. Am J Hypertens. 1995;8(12):1154–9.

    Article  PubMed  Google Scholar 

  33. Aronson S, Dyke CM, Stierer KA, Levy JH, Cheung AT, Lumb PD, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008;107(4):1110–21.

    Article  CAS  PubMed  Google Scholar 

  34. Ge W, Ren J. Combined L-/T-type calcium channel blockers: ready for prime time. Hypertension. 2009;53(4):592–4.

    Article  CAS  PubMed  Google Scholar 

  35. Weiss N, Zamponi GW. T-type calcium channels: from molecule to therapeutic opportunities. Int J Biochem Cell Biol. 2019;108:34–9.

    Article  CAS  PubMed  Google Scholar 

  36. Abe M, Soma M. Multifunctional L/N- and L/T-type calcium channel blockers for kidney protection. Hypertens Res. 2015;38(12):804–6.

    Article  CAS  PubMed  Google Scholar 

  37. Koh KK, Quon MJ, Lee SJ, Han SH, Ahn JY, Kim JA, et al. Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in nondiabetic patients with hypertension. Diabetes Care. 2007 Jun;30(6):1605–7.

    Article  CAS  PubMed  Google Scholar 

  38. Efonidipine Pubchem. 2021. Available from https://pubchem.ncbi.nlm.nih.gov/compound/Efonidipine.

  39. Azelnidipine. Pubchem. 2021. Available from https://pubchem.ncbi.nlm.nih.gov/compound/Azelnidipine

  40. Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res. 2003;26(3):201–8.

    Article  CAS  PubMed  Google Scholar 

  41. Yagil Y, Lustig A. Azelnidipine (CS-905), a novel dihydropyridine calcium channel blocker with gradual onset and prolonged duration of action. Cardiovasc Drug Rev. 1995;13(2):137–48.

    Article  CAS  Google Scholar 

  42. Sada T, Saito H. Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker. Nihon Yakurigaku Zasshi. 2003;122(6):539–47.

    Article  CAS  PubMed  Google Scholar 

  43. Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, et al. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. Am J Med. 2012;125(10):981–190.

    Article  CAS  PubMed  Google Scholar 

  44. Kim-Mitsuyama S, Ogawa H, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. Kidney Int. 2013;83(1):167–76.

    Article  CAS  PubMed  Google Scholar 

  45. Benidipine Pubchem. 2021. Available from https://pubchem.ncbi.nlm.nih.gov/compound/Benidipine.

  46. Tomino Y. Renoprotective effects of the L-/T-type calcium channel blocker benidipine in patients with hypertension. Curr Hypertens Rev. 2013;9(2):108–14.

    Article  CAS  PubMed  Google Scholar 

  47. Kosaka H, Hirayama K, Yoda N, Sasaki K, Kitayama T, Kusaka H, et al. The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol. 2010;635(1-3):49–55.

    Article  CAS  PubMed  Google Scholar 

  48. Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29(8):1649–59.

    Article  CAS  PubMed  Google Scholar 

  49. Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T. Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial. Hypertens Res. 2017;40(4):376–84.

    Article  CAS  PubMed  Google Scholar 

  50. Thamcharoen N, Susantitaphong P, Wongrakpanich S, Chongsathidkiet P, Tantrachoti P, Pitukweerakul S, et al. Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis. Hypertens Res. 2015;38(12):847–55.

    Article  CAS  PubMed  Google Scholar 

  51. Tan HW, Li L, Zhang W, Ma ZY, Zhong XZ, Zhang Y. Effect of cilnidipine on left ventricular function in hypertensive patients as assessed by tissue Doppler Tei index. J Hum Hypertens. 2006;20(8):618–24.

    Article  CAS  PubMed  Google Scholar 

  52. Onose Y, Oki T, Yamada H, Manabe K, Kageji Y, Matsuoka M, et al. Effect of cilnidipine on left ventricular diastolic function in hypertensive patients as assessed by pulsed Doppler echocardiography and pulsed tissue Doppler imaging. Jpn Circ J. 2001;65(4):305–9.

    Article  CAS  PubMed  Google Scholar 

  53. Hayashi K. L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers. Hypertens Res. 2011;34(8):910–2.

    Article  CAS  PubMed  Google Scholar 

  54. Fukumoto S, Ishimura E, Motoyama K, Morioka T, Kimoto E, Wakikawa K, et al. Cilnidipine vs L-type calcium channel blockers evaluation of antihypertensive renoprotective effects in diabetic patients (CLEARED) study investigators. Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria. Diabetes Res Clin Pract. 2012;97(1):91–8.

    Article  CAS  PubMed  Google Scholar 

  55. Hayashi K, Saruta T, Goto Y, Ishii M. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res. 2010;33:1211–20.

    Article  CAS  PubMed  Google Scholar 

  56. Kario K, Ando S, Kido H, Nariyama J, Takiuchi S, Yagi T, et al. The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE. J Clin Hypertens. 2013;15(2):133–42.

    Article  CAS  Google Scholar 

  57. Kario K, Nariyama J, Kido H, Ando S, Takiuchi S, Eguchi K, et al. Effect of a novel calcium channel blocker on abnormal nocturnal blood pressure in hypertensive patients. J Clin Hypertens. 2013;15(7):465–72.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Karuna Hospital, Borivali West and Shilpa Medical Research Centre, Mumbai, India

    Mangesh Tiwaskar

Authors
  1. Mangesh Tiwaskar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Apollo Hospitals, Apollo Institute for Blood Pressure Management, Hyderabad, India

    C. Venkata S. Ram

  2. Head, Division of Nephrology Department of Medicine, Yong Loo Lin Sch of Med Natl Univ of Sin, Singapore, Singapore

    Boon Wee Jimmy Teo

  3. Department of Cardiology, Hero DMC Heart Institute, Dayanand Medical College, Ludhiana, Punjab, India

    Gurpreet S. Wander

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tiwaskar, M. (2022). Newer Calcium Channel Blockers. In: Ram, C.V.S., Teo, B.W.J., Wander, G.S. (eds) Hypertension and Cardiovascular Disease in Asia. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-030-95734-6_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-95734-6_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-95733-9

  • Online ISBN: 978-3-030-95734-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation